MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

10369	Companies
216081	Keywords
145800	Articles
114420	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 07/22/2024 at 14:00, 1 year 9 months ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
MIRA Pharmaceuticals reveals new promising preclinical data for Ketamir-2, a novel oral ketamine analog, indicating potential advantages for treating neurological and neuropsychiatric disorders

Preclinical Study Neurological Disorders MIRA Pharmaceuticals Neuropsychiatric Disorders Ketamir-2
BRIEF

published on 07/15/2024 at 13:05, 1 year 9 months ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Pharmaceuticals Preclinical Studies MIRA-55 Anxiety Treatment THC Comparison
BRIEF

published on 07/15/2024 at 13:05, 1 year 9 months ago

Mira Pharmaceuticals annonce des résultats prometteurs pour MIRA-55 dans plusieurs tests précliniques par rapport au THC

Médicaments Etudes Précliniques MIRA-55 Traitement De L'anxiété Comparaison Du THC
PRESS RELEASE

published on 07/15/2024 at 13:00, 1 year 9 months ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
MIRA Pharmaceuticals, Inc. confirms promising findings on new oral pharmaceutical marijuana analog, MIRA-55, as a potential treatment for neurological and neuropsychiatric disorders. Comparison to THC shows enhanced efficacy and consistent anxiolytic effects

Neurological Disorders Preclinical Studies MIRA-55 MIRA Pharmaceuticals Neuropsychiatric Disorders

Accesswire

Published on 05/08/2026 at 14:00, 13 minutes ago

BlackBerry Announces Renewal of Normal Course Issuer Bid Share Buyback Program
Published on 05/08/2026 at 14:00, 13 minutes ago

Loop Industries to Host Fourth Quarter 2025 Earnings Conference Call
Published on 05/08/2026 at 12:48, 1 hour 25 minutes ago

Ur-Energy Reports Q1 2026 Results and Announces Conference Call and Webcast
Published on 05/08/2026 at 12:30, 1 hour 43 minutes ago

Trans Canada Gold Completes Second Tranche of the Non-Brokered Private Placement and Prepares for Drilling at the Harrison Lake Gold Project
Published on 05/08/2026 at 10:30, 3 hours 43 minutes ago

Previewing the Product Logic Behind Waton’s Next AI Trading Platform

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 13:53, 20 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/08/2026 at 13:35, 38 minutes ago

DeFi Technologies Announces Partnership with OMFIF's Digital Monetary Institute and Confirms Participation at the Digital Money Summit 2026 in London
Published on 05/08/2026 at 13:05, 1 hour 8 minutes ago

Philadelphia Soccer 2026 Opens Media Credentialing and Fan Registration for FIFA Fan Festival™ Philadelphia
Published on 05/08/2026 at 12:01, 2 hours 11 minutes ago

Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 05/08/2026 at 11:58, 2 hours 14 minutes ago

EQS-Adhoc: Aurubis AG: Aurubis AG raises 2025/26 full-year forecast based on improved market outlook

Les Echos

Published on 05/07/2026 at 19:15, 18 hours 58 minutes ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 18 hours 58 minutes ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 19 hours 7 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 19 hours 7 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 19 hours 13 minutes ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE